Preparation of bismuth sulfide nanoparticles as targeted biocompatible nano-radiosensitizer and carrier of methotrexate

In this study, Bi₂S₃@BSA–Bio–MTX nanoparticles (NPs) were synthesized for the first time by bovine serum albumin (BSA)-mediated biomineralization (Bi₂S₃@BSA NPs) followed by covalent bonding of biotin (Bio) and methotrexate (MTX) on the surface of the Bi₂S₃@BSA NPs via carbodiimide chemistry. The synthesized NPs were globular and exhibited uniform morphology with a hydrodynamic diameter of 107.6 ± 6.81 nm (mean ± standard deviation) and zeta potential of −20.9 ± 2.18 mV. Drug release from Bi₂S₃@BSA–Bio–MTX NPs indicated an enzyme-dependent release pattern. The in vitro biocompatibility of NPs was confirmed by investigating their cytotoxicity against the HEK-293 cell line and hemolysis assay test, whereas the in vivo biocompatibility of the NPs was evaluated and confirmed by the lethal dose 50 (LD₅₀) test. To evaluate the in vitro anticancer activity of the functionalized NPs and MTX, their cytotoxic effects was assessed against 4T1 cancer cells by 5-dimethylthiazol-z-yl)-2,5-diphenyltetrazolium bromide (MTT) assay with and without X-ray radiation. Results showed that Bi₂S₃@BSA–Bio–MTX NPs have excellent anticancer activity, especially following X-ray radiation.